3 August 2016 - NICE has issued draft guidance on the use of apremilast for the treatment of patients with moderate to severe  psoriasis.

Apremilast is recommended as an option for treating chronic plaque psoriasis in adults whose disease has not responded to other systemic therapies, for example, ciclosporin, methotrexate or PUVA (psoralen and ultraviolet-A light), or these treatments are contra-indicated or the person cannot tolerate them, only when:

• the disease is severe, as defined by a total Psoriasis Area Severity Index of 10 or more and a Dermatology Life Quality Index of more than 10
• the company provides apremilast with the discount agreed in the patient access scheme.

Apremilast will be considered at a second appraisal committee meeting on 7 September 2016.

Read draft guidance for apremilast